Alectinib is a highly specific ALK inhibitor with good efficacy and tolerability demonstrated in phase II studies in patients with NSCLC harbouring ALK rearrangements (NP28673 [NCT01801111] and NP28761 [NCT01871805]) (Ou et al, 2016; Shaw et al, 2016). The gene discussed is ALK; the disease is non-small cell lung carcinoma.